Ipsen To File Cabozantinib For Liver Cancer In 1H 2018

Exelixis and Ipsen's Phase III CELESTIAL trial succeeds: cabozantinib meets primary overall survival endpoint in patients with advanced liver cancer. 

Cirrhosis
Ipsen to file cabozantinib for liver cancer in Europe after Positive Phase III

Ipsen will file cancer therapy cabozantinib in Europe for the treatment of advanced hepatocellular carcinoma (HCC) during the first half of next year on the back of positive data from the Phase III CELESTIAL trial; its partner Exelixis will file a supplemental new drug application for cabozantinib in the US for advanced HCC in the first quarter of 2018. 

Cabozantinib is already approved in the US and Europe for the treatment of thyroid cancer (sold as Cometriq) and for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.